Seidman, Andrew

Publications

Sort by

Co-Author Network

selected publications

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of neuro-oncology. 2020 Academic Article GET IT
Times cited: 52
"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. Journal of oncology practice. 2019 Academic Article GET IT
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 9
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 38
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 242
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clinical breast cancer. 2016 Academic Article GET IT
Times cited: 86
When to Combine Endocrine Therapy With a New Agent for Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women. Oncology (Williston Park, N.Y.). 2016 Academic Article GET IT
Times cited: 1
Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. International journal of radiation oncology, biology, physics. 2014 Academic Article GET IT
Times cited: 30
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 140
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The oncologist. 2014 Academic Article GET IT
Times cited: 11
Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 23
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 25
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Editorial Article GET IT
Times cited: 3
Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. 2013 Academic Article GET IT
Times cited: 20
Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. The breast journal. 2012 Academic Article GET IT
Times cited: 8
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. The breast journal. 2012 Conference Paper GET IT
Times cited: 8
Limited overall survival in patients with brain metastases from triple negative breast cancer. The breast journal. 2012 Academic Article GET IT
Times cited: 19
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 22
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 51
How long is long enough?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 3
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 28
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 51
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 27
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 54
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 79
A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 8
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast cancer research and treatment. 2010 Article GET IT
Times cited: 6
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 20
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer immunology, immunotherapy : CII. 2010 Academic Article GET IT
Times cited: 16
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of cancer research and clinical oncology. 2009 Academic Article GET IT
Times cited: 175
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 110
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clinical breast cancer. 2008 Information Resource GET IT
Times cited: 25
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 34
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 492
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 48
Emerging targeted therapies for breast cancer. Hematology/oncology clinics of North America. 2007 Information Resource GET IT
Times cited: 4
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 9
Taxanes in breast cancer: an update. Current oncology reports. 2007 Information Resource GET IT
Times cited: 35
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Molecular diagnosis & therapy. 2007 Information Resource GET IT
Times cited: 18
Cardiac dysfunction associated with trastuzumab. Expert opinion on drug safety. 2006 Information Resource GET IT
Times cited: 37
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical breast cancer. 2006 Academic Article GET IT
Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park, N.Y.). 2006 Information Resource GET IT
Times cited: 15
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 70
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nature clinical practice. Oncology. 2006 Article GET IT
Times cited: 3
"Will weekly work"? Seems to be so.... Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Editorial Article GET IT
Times cited: 26
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer. 2005 Academic Article GET IT
Emerging targeted therapies for breast cancer. Oncology (Williston Park, N.Y.). 2005 Information Resource GET IT
Times cited: 8
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment. 2005 Academic Article GET IT
Times cited: 76
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Academic Article GET IT
Times cited: 105
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer investigation. 2005 Academic Article GET IT
Times cited: 38
Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park, N.Y.). 2004 Information Resource GET IT
Times cited: 9
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2004 Academic Article GET IT
New advances in taxane therapy: the next generation. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 28
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 54
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer. Oncology (Williston Park, N.Y.). 2003 Information Resource GET IT
Times cited: 2
Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 26
Cardiac dysfunction in clinical trials of trastuzumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Article GET IT
HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park, N.Y.). 2002 Information Resource GET IT
Times cited: 64
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 25
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 73
Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 1152
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 75
An update on epidermal growth factor receptor inhibitors. Current oncology reports. 2002 Information Resource GET IT
Times cited: 26
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 29
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 530
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast cancer research and treatment. 2001 Academic Article GET IT
Times cited: 174
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 75
Breast disease. Introduction. Breast disease. 2001 Academic Article GET IT
The evolving role of gemcitabine in the management of breast cancer. Oncology. 2001 Information Resource GET IT
Times cited: 17
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 656
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in oncology. 1999 Academic Article GET IT
Times cited: 256
Update on the management of advanced breast cancer. Oncology (Williston Park, N.Y.). 1999 Information Resource GET IT
Times cited: 37
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 49
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 11
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 86
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Review GET IT
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer investigation. 1998 Academic Article GET IT
Times cited: 10
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert opinion on investigational drugs. 1997 Academic Article GET IT
Phase II study of semisynthetic paclitaxel in metastatic breast cancer. European journal of cancer. 1997 Academic Article GET IT
Times cited: 12
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Journal of neuro-oncology. 1997 Academic Article GET IT
Times cited: 149
Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996 Academic Article GET IT
Times cited: 114
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 151
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 1234
Chemotherapy for advanced breast cancer: a current perspective. Seminars in oncology. 1996 Information Resource GET IT
Times cited: 24
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Seminars in oncology. 1996 Academic Article GET IT
Times cited: 27
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 142
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Seminars in oncology. 1995 Academic Article GET IT
Times cited: 23
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 204
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. Journal of the National Cancer Institute. 1995 Academic Article GET IT
Times cited: 85
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995 Academic Article GET IT
Times cited: 101
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 217
The emerging role of paclitaxel in breast cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Information Resource GET IT
Times cited: 54
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1994 Academic Article GET IT
Times cited: 70
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. Oncology. 1994 Academic Article GET IT
Times cited: 3
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Article GET IT
Times cited: 28
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 132
Single-agent use of Taxol (paclitaxel) in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1994 Information Resource GET IT
Times cited: 15
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. International journal of clinical & laboratory research. 1994 Review GET IT
Times cited: 75
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. Annals of the New York Academy of Sciences. 1993 Academic Article GET IT
Times cited: 2
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 231
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 98
Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer. 1993 Academic Article GET IT
Times cited: 14
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report. Journal of the National Cancer Institute. Monographs. 1993 Academic Article GET IT
Times cited: 12
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. The Journal of urology. 1992 Academic Article GET IT
Times cited: 186
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer. 1991 Academic Article GET IT
Times cited: 88

more ...

less ...

Background

education and training

M.D., Medical College of Pennsylvania and Hahnemann University 1985
B.S., State University of New York at Binghamton 1981

Contact

full name

Andrew Seidman

VIVO Weill Cornell Medical College

Andrew Seidman Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name